Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 58, Issue 5, Pages 1022-1036
Publisher
Informa UK Limited
Online
2016-09-21
DOI
10.1080/10428194.2016.1228927
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
- (2016) Guillermo Garcia-Manero et al. LANCET ONCOLOGY
- Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
- (2015) Ashkan Emadi et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2015) Paolo Strati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification
- (2015) P. Strati et al. BLOOD
- Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?
- (2015) Alesia A. Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thrombopoiesis-stimulating agents and myelodysplastic syndromes
- (2015) Charlotte K. Brierley et al. BRITISH JOURNAL OF HAEMATOLOGY
- Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
- (2015) Thomas Prebet et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
- (2015) Raoul Tibes et al. Journal of Hematology & Oncology
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
- (2015) M G Della Porta et al. LEUKEMIA
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2015) N Daver et al. LEUKEMIA
- Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
- (2015) Rupa Narayan et al. LEUKEMIA & LYMPHOMA
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Sonic Hedgehog Produced by Bone Marrow-Derived Mesenchymal Stromal Cells Supports Cell Survival in Myelodysplastic Syndrome
- (2015) Jixue Zou et al. Stem Cells International
- Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
- (2015) Courtney D DiNardo et al. Lancet Haematology
- Expanding role of lenalidomide in hematologic malignancies
- (2015) Nilanjan Ghosh et al. Cancer Management and Research
- Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
- (2015) Oncotarget
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
- (2014) Mark Kirschbaum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia
- (2014) Aristoteles Giagounidis et al. CANCER
- A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine
- (2014) Tobias Svensson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents
- (2014) Bing Z. Carter et al. JNCI-Journal of the National Cancer Institute
- Myelodysplastic syndromes
- (2014) Lionel Adès et al. LANCET
- Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities
- (2014) S Fulda LEUKEMIA
- Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis
- (2014) Jie Jin et al. PLoS One
- Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
- (2014) M Tobiasson et al. Blood Cancer Journal
- Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2014) P Tan et al. Blood Cancer Journal
- High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
- (2013) C. Kelaidi et al. ANNALS OF HEMATOLOGY
- The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
- (2013) R. F. Schlenk et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Current therapy of myelodysplastic syndromes
- (2013) Amer M. Zeidan et al. BLOOD REVIEWS
- Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1-Risk Myelodysplastic Syndromes
- (2013) C. Fili et al. CLINICAL CANCER RESEARCH
- Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents
- (2013) Valeria Santini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Isocitrate dehydrogenase mutations in leukemia
- (2013) Anna Sophia McKenney et al. JOURNAL OF CLINICAL INVESTIGATION
- Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
- (2013) U Platzbecker et al. LEUKEMIA
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
- (2013) J.-A. Losman et al. SCIENCE
- Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis
- (2013) L Steinhart et al. Cell Death & Disease
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
- (2012) Julie Schanz et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
- (2012) Peter L. Greenberg et al. LEUKEMIA & LYMPHOMA
- Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
- (2011) Djordje Atanackovic et al. AMERICAN JOURNAL OF HEMATOLOGY
- Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
- (2011) C. R. Cogle et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study
- (2011) Aaron D. Schimmer et al. Clinical Lymphoma Myeloma & Leukemia
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
- (2011) L. Malcovati et al. HAEMATOLOGICA
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
- (2011) R. Itzykson et al. LEUKEMIA RESEARCH
- Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
- (2010) H. M. Kantarjian et al. BLOOD
- Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors
- (2010) A. Merchant et al. BLOOD
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
- (2010) Thomas Prebet et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
- (2009) Aaron D. Schimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
- (2008) Janice Gabrilove et al. BRITISH JOURNAL OF HAEMATOLOGY
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
- (2008) Jennifer S. Carew et al. CANCER LETTERS
- Acetylation of non-histone proteins modulates cellular signalling at multiple levels
- (2008) Stephanie Spange et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now